Adrenoleukodystrophy Drugs Market, Global Outlook and Forecast 2023-2029

Report ID: MMG51474 | Category: Pharma & Healthcare | Pages: 77 | Format: PDF | Published Date: February 21,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP). 

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Drugs. This report contains market size and forecasts of Adrenoleukodystrophy Drugs in global, including the following market information:
Global Adrenoleukodystrophy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Adrenoleukodystrophy Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Adrenoleukodystrophy Drugs companies in 2022 (%)
The global Adrenoleukodystrophy Drugs market was valued at US$ 347.6 million in 2022 and is projected to reach US$ 936.8 million by 2029, at a CAGR of 15.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adrenoleukodystrophy Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adrenoleukodystrophy Drugs Market Segment Percentages, by Type, 2022 (%)
    Hormone Replacement
    Transplant
    Others
Global Adrenoleukodystrophy Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adrenoleukodystrophy Drugs Market Segment Percentages, by Application, 2022 (%)
    Childhood Cerebral ALD
    Adrenomyeloneuropathy (AMN)
    Addison-only
    Others
Global Adrenoleukodystrophy Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Adrenoleukodystrophy Drugs Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adrenoleukodystrophy Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Adrenoleukodystrophy Drugs revenues share in global market, 2022 (%)
Key companies Adrenoleukodystrophy Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Adrenoleukodystrophy Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Bluebird Bio Inc
    NeuroVia, Inc.
    Orpheris, Inc.
    Minoryx
    MedDay Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adrenoleukodystrophy Drugs, market overview.
Chapter 2: Global Adrenoleukodystrophy Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Adrenoleukodystrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adrenoleukodystrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Adrenoleukodystrophy Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Adrenoleukodystrophy Drugs Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Adrenoleukodystrophy Drugs Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Adrenoleukodystrophy Drugs Overall Market Size
    2.1 Global Adrenoleukodystrophy Drugs Market Size: 2022 VS 2029
    2.2 Global Adrenoleukodystrophy Drugs Revenue, Prospects & Forecasts: 2018-2029
    2.3 Global Adrenoleukodystrophy Drugs Sales: 2018-2029
3 Company Landscape
    3.1 Top Adrenoleukodystrophy Drugs Players in Global Market
    3.2 Top Global Adrenoleukodystrophy Drugs Companies Ranked by Revenue
    3.3 Global Adrenoleukodystrophy Drugs Revenue by Companies
    3.4 Global Adrenoleukodystrophy Drugs Sales by Companies
    3.5 Global Adrenoleukodystrophy Drugs Price by Manufacturer (2018-2023)
    3.6 Top 3 and Top 5 Adrenoleukodystrophy Drugs Companies in Global Market, by Revenue in 2022
    3.7 Global Manufacturers Adrenoleukodystrophy Drugs Product Type
    3.8 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Players in Global Market
        3.8.1 List of Global Tier 1 Adrenoleukodystrophy Drugs Companies
        3.8.2 List of Global Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies
4 Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Adrenoleukodystrophy Drugs Market Size Markets, 2022 & 2029
        4.1.2 Hormone Replacement
        4.1.3 Transplant
        4.1.4 Others
    4.2 By Type - Global Adrenoleukodystrophy Drugs Revenue & Forecasts
        4.2.1 By Type - Global Adrenoleukodystrophy Drugs Revenue, 2018-2023
        4.2.2 By Type - Global Adrenoleukodystrophy Drugs Revenue, 2024-2029
        4.2.3 By Type - Global Adrenoleukodystrophy Drugs Revenue Market Share, 2018-2029
    4.3 By Type - Global Adrenoleukodystrophy Drugs Sales & Forecasts
        4.3.1 By Type - Global Adrenoleukodystrophy Drugs Sales, 2018-2023
        4.3.2 By Type - Global Adrenoleukodystrophy Drugs Sales, 2024-2029
        4.3.3 By Type - Global Adrenoleukodystrophy Drugs Sales Market Share, 2018-2029
    4.4 By Type - Global Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Adrenoleukodystrophy Drugs Market Size, 2022 & 2029
        5.1.2 Childhood Cerebral ALD
        5.1.3 Adrenomyeloneuropathy (AMN)
        5.1.4 Addison-only
        5.1.5 Others
    5.2 By Application - Global Adrenoleukodystrophy Drugs Revenue & Forecasts
        5.2.1 By Application - Global Adrenoleukodystrophy Drugs Revenue, 2018-2023
        5.2.2 By Application - Global Adrenoleukodystrophy Drugs Revenue, 2024-2029
        5.2.3 By Application - Global Adrenoleukodystrophy Drugs Revenue Market Share, 2018-2029
    5.3 By Application - Global Adrenoleukodystrophy Drugs Sales & Forecasts
        5.3.1 By Application - Global Adrenoleukodystrophy Drugs Sales, 2018-2023
        5.3.2 By Application - Global Adrenoleukodystrophy Drugs Sales, 2024-2029
        5.3.3 By Application - Global Adrenoleukodystrophy Drugs Sales Market Share, 2018-2029
    5.4 By Application - Global Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
    6.1 By Region - Global Adrenoleukodystrophy Drugs Market Size, 2022 & 2029
    6.2 By Region - Global Adrenoleukodystrophy Drugs Revenue & Forecasts
        6.2.1 By Region - Global Adrenoleukodystrophy Drugs Revenue, 2018-2023
        6.2.2 By Region - Global Adrenoleukodystrophy Drugs Revenue, 2024-2029
        6.2.3 By Region - Global Adrenoleukodystrophy Drugs Revenue Market Share, 2018-2029
    6.3 By Region - Global Adrenoleukodystrophy Drugs Sales & Forecasts
        6.3.1 By Region - Global Adrenoleukodystrophy Drugs Sales, 2018-2023
        6.3.2 By Region - Global Adrenoleukodystrophy Drugs Sales, 2024-2029
        6.3.3 By Region - Global Adrenoleukodystrophy Drugs Sales Market Share, 2018-2029
    6.4 North America
        6.4.1 By Country - North America Adrenoleukodystrophy Drugs Revenue, 2018-2029
        6.4.2 By Country - North America Adrenoleukodystrophy Drugs Sales, 2018-2029
        6.4.3 US Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.4.4 Canada Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.4.5 Mexico Adrenoleukodystrophy Drugs Market Size, 2018-2029
    6.5 Europe
        6.5.1 By Country - Europe Adrenoleukodystrophy Drugs Revenue, 2018-2029
        6.5.2 By Country - Europe Adrenoleukodystrophy Drugs Sales, 2018-2029
        6.5.3 Germany Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.5.4 France Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.5.5 U.K. Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.5.6 Italy Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.5.7 Russia Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.5.8 Nordic Countries Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.5.9 Benelux Adrenoleukodystrophy Drugs Market Size, 2018-2029
    6.6 Asia
        6.6.1 By Region - Asia Adrenoleukodystrophy Drugs Revenue, 2018-2029
        6.6.2 By Region - Asia Adrenoleukodystrophy Drugs Sales, 2018-2029
        6.6.3 China Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.6.4 Japan Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.6.5 South Korea Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.6.6 Southeast Asia Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.6.7 India Adrenoleukodystrophy Drugs Market Size, 2018-2029
    6.7 South America
        6.7.1 By Country - South America Adrenoleukodystrophy Drugs Revenue, 2018-2029
        6.7.2 By Country - South America Adrenoleukodystrophy Drugs Sales, 2018-2029
        6.7.3 Brazil Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.7.4 Argentina Adrenoleukodystrophy Drugs Market Size, 2018-2029
    6.8 Middle East & Africa
        6.8.1 By Country - Middle East & Africa Adrenoleukodystrophy Drugs Revenue, 2018-2029
        6.8.2 By Country - Middle East & Africa Adrenoleukodystrophy Drugs Sales, 2018-2029
        6.8.3 Turkey Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.8.4 Israel Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.8.5 Saudi Arabia Adrenoleukodystrophy Drugs Market Size, 2018-2029
        6.8.6 UAE Adrenoleukodystrophy Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
    7.1 Bluebird Bio Inc
        7.1.1 Bluebird Bio Inc Company Summary
        7.1.2 Bluebird Bio Inc Business Overview
        7.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Product Offerings
        7.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales and Revenue in Global (2018-2023)
        7.1.5 Bluebird Bio Inc Key News & Latest Developments
    7.2 NeuroVia, Inc.
        7.2.1 NeuroVia, Inc. Company Summary
        7.2.2 NeuroVia, Inc. Business Overview
        7.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
        7.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales and Revenue in Global (2018-2023)
        7.2.5 NeuroVia, Inc. Key News & Latest Developments
    7.3 Orpheris, Inc.
        7.3.1 Orpheris, Inc. Company Summary
        7.3.2 Orpheris, Inc. Business Overview
        7.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
        7.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales and Revenue in Global (2018-2023)
        7.3.5 Orpheris, Inc. Key News & Latest Developments
    7.4 Minoryx
        7.4.1 Minoryx Company Summary
        7.4.2 Minoryx Business Overview
        7.4.3 Minoryx Adrenoleukodystrophy Drugs Major Product Offerings
        7.4.4 Minoryx Adrenoleukodystrophy Drugs Sales and Revenue in Global (2018-2023)
        7.4.5 Minoryx Key News & Latest Developments
    7.5 MedDay Pharmaceuticals
        7.5.1 MedDay Pharmaceuticals Company Summary
        7.5.2 MedDay Pharmaceuticals Business Overview
        7.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Major Product Offerings
        7.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales and Revenue in Global (2018-2023)
        7.5.5 MedDay Pharmaceuticals Key News & Latest Developments
8 Global Adrenoleukodystrophy Drugs Production Capacity, Analysis
    8.1 Global Adrenoleukodystrophy Drugs Production Capacity, 2018-2029
    8.2 Adrenoleukodystrophy Drugs Production Capacity of Key Manufacturers in Global Market
    8.3 Global Adrenoleukodystrophy Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
    9.1 Market Opportunities & Trends
    9.2 Market Drivers
    9.3 Market Restraints
10 Adrenoleukodystrophy Drugs Supply Chain Analysis
    10.1 Adrenoleukodystrophy Drugs Industry Value Chain
    10.2 Adrenoleukodystrophy Drugs Upstream Market
    10.3 Adrenoleukodystrophy Drugs Downstream and Clients
    10.4 Marketing Channels Analysis
        10.4.1 Marketing Channels
        10.4.2 Adrenoleukodystrophy Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
    12.1 Note
    12.2 Examples of Clients
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Adrenoleukodystrophy Drugs Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?